GlassScriptPhysician profile
Pranay Kathuria
NPI 1073583431
$20,757.51
in general payments reported to CMS, 2019-2025
25 companies · $3,330 in 2025
The $3,330 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $1,271 · 2021: $5,235 · 2022: $5,620 · 2023: $3,070 · 2024: $1,636 · 2025: $3,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,947 · Food and Beverage: $2,851 · Consulting Fee: $2,219 · Education: $18.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,947.12 |
| Food and Beverage | $2,850.85 |
| Consulting Fee | $2,218.85 |
| Education | $18.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $13,948.36 | 2021-2024 | |
| Calliditas Therapeutics US INC. | $2,340.96 | 2025 | Tarpeyo |
| Horizon Therapeutics Plc | $1,334.62 | 2020-2023 | Krystexxa |
| Amgen INC. | $564.57 | 2021-2025 | Krystexxa, Tavneos, Repatha |
| Astrazeneca Pharmaceuticals LP | $490.33 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.36 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $219.58 | 2024-2025 | |
| Glaxosmithkline, LLC. | $196.58 | 2022-2025 | Arexvy |
| Alexion Pharmaceuticals, INC. | $167.97 | 2019-2025 | Ultomiris |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Daiichi Sankyo INC. | $121.64 | 2023 | Injectafer |
| Lilly USA, LLC | $109.44 | 2023 | Mounjaro |
| Fresenius USA Marketing, INC. | $104.90 | 2022-2025 | Velphoro |
| Mallinckrodt Enterprises LLC | $99.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $88.57 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $75.09 | 2024-2025 | Jynarque |
| Merck Sharp & Dohme LLC | $57.46 | 2024-2025 | Prevymis, Zerbaxa |
| Novo Nordisk INC | $45.38 | 2025 | Ozempic, Rybelsus |
| Baxter Healthcare | $43.13 | 2021 | |
| Mallinckrodt Hospital Products INC. | $37.67 | 2025 | Terlivaz |
| Veloxis Pharmaceuticals, INC. | $29.75 | 2020 | |
| Ardelyx, INC. | $23.41 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $16.31 | 2020 | |
| Vifor Pharma, INC. | $15.87 | 2025 | Veltassa |
| Azurity Pharmaceuticals, INC. | $15.58 | 2025 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranay Kathuria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.